ArticleJournal of asthma and allergy2026
Circulating TFH2 Cell Expansion and GZMK
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allergic rhinitis (AR) is a prevalent condition characterized by an immunoglobulin E (IgE)-mediated immune response. T follicular helper (TFH) cells regulate B-cell differentiation and antibody production, and circulating TFH2 cells are closely associated with type 2 humoral immunity and IgE-related responses in AR. However, whether AR is marked by isolated TFH2 expansion or broader remodeling of circulating TFH (cTFH) subsets, including TFH1-related heterogeneity, remains unclear. Methods: A total of 56 participants were enrolled, including 39 patients with AR and 17 healthy controls (HC). Flow cytometry was performed in 36 patients with AR and 14 HC to quantify cTFH subsets and activation states. Single-cell RNA sequencing (scRNA-seq) was conducted in an independent exploratory cohort comprising 3 patients with AR and 3 HC to characterize TFH transcriptional heterogeneity, based on canonical transcriptional programs. Results: Flow cytometry demonstrated that cTFH2 cell frequencies were significantly increased in patients with AR and positively correlated with disease severity. Activated CCR7^low PD-1^high cTFH cells were also elevated, indicating enhanced TFH activation. Further scRNA-seq analysis identified six transcriptionally distinct TFH clusters, with TFH2-like transcriptional signatures enriched in patients with AR, consistent with flow cytometric findings. Notably, a GZMK Conclusion: This study demonstrates the expansion of cTFH2 and GZMK
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.